정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1689 | Terminated | DUR-928 in Subjects With SARS-CoV-2 With Acute Lung, Liver or Kidney Injury | SARS-CoV 2 | Drug: DUR-928 Drug: Placebo |
Phase 2 | Durect | INDUSTRY | 2 | All | 18 Years ~ 80 Years | Site 03, Newark, New Jersey, United States |
| 1688 | Recruiting | Duvelisib Ameliorates Manifestations of Pneumonia in Established Novel Coronavirus Infection (COVID-19) | COVID-19 | Drug: Duvelisib Drug: Placebo |
Phase 2 | Emory University, Verastem, Inc., University of Pennsylvania | OTHER | 80 | All | 18 Years | Emory Saint Joseph's Hospital, Atlanta, Georgia, United States Emory University Hospital Midtown, Atlanta, Georgia, United States Emory University Hospital, Atlanta, Georgia, United States |
| 1687 | Recruiting | Duvelisib to Combat COVID-19 | COVID-19 | Drug: Duvelisib Procedure: Peripheral blood draw Drug: Placebo |
Phase 2 | Washington University School of Medicine, Verastem, Inc. | OTHER | 28 | All | 18 Years | Missouri Baptist Medical Center, Saint Louis, Missouri, United States Washington University School of Medicine, Saint Louis, Missouri, United States |
| 1686 | Not yet recruiting | DYNAMIC Study (DoxycYcliNe AMbulatoIre COVID-19) | COVID19 | Drug: Doxycycline Drug: Placebo |
Phase 3 | Nantes University Hospital | OTHER | 330 | All | 46 Years | CHU Avicenne - APHP, Bobigny, France CHU Bordeaux, Bordeaux, France CHU Caen, Caen, France CHU Dijon, Dijon, France CHU Grenoble, Grenoble, France CHU Nantes, Nantes, France |
| 1685 | Recruiting | Dynamics of the Immune Responses to Repeat Influenza Vaccination Exposures | Influenza, Human | Biological: FluBlok Other: Placebo |
Phase 4 | The University of Hong Kong, University of Chicago, National Institute of Allergy and Infectious Diseases (NIAID) | OTHER | 1103 | All | 18 Years ~ 45 Years | The University of Hong Kong, Hong Kong, Hong Kong |
| 1684 | Recruiting | Early Convalescent Plasma Therapy for High-risk Patients With COVID-19 in Primary Care (the CoV-Early Study) | Covid19 | Biological: ConvP Biological: FFP |
Phase 3 | Erasmus Medical Center, Sanquin Plasma Products BV, ZonMw: The Netherlands Organisation for Health Research and Development, Leiden University Medical Center | OTHER | 690 | All | 50 Years | Erasmus Medical Center, Rotterdam, Zuid-Holland, Netherlands Meander Medisch Centrum, Amersfoort, Netherlands Rijnstate Ziekenhuis, Arnhem, Netherlands Amphia Ziekenhuis, Breda, Netherlands Groene Hart Ziekenhuis, Gouda, Netherlands University Medical Center Groningen (UMCG), Groningen, Netherlands Spaarne Gasthuis, Haarlem, Netherlands Medisch Centrum Leeuwarden, Leeuwarden, Netherlands Leids Universitair Medisch Centrum, Leiden, Netherlands Sint Antonius Ziekenhuis, Nieuwegein, Netherlands Bernhoven Hospital, Uden, Netherlands |
| 1683 | Active, not recruiting | Early Intervention in COVID-19: Favipiravir Verses Standard Care | Coronavirus Infection | Drug: Favipiravir Other: Standard of care management |
Phase 3 | Chelsea and Westminster NHS Foundation Trust, NEAT ID Foundation, FUJIFILM Toyama Chemical Co., Ltd., Imperial College London | OTHER | 502 | All | 18 Years | Grupo Hospitalar Conceicao, Porto Alegre, Brazil Fundacao Oswaldo Cruz - Instituto Nacional de Infectologia Evandro Chagas (Fiocruz/INI), Rio De Janeiro, Brazil Instituto Nacional de Ciencias Medicas y Nutricion, Salvador Zubiran, Mexico City, Mexico Hull University Teaching Hospitals NHS Trust - Castle Hill Hospital, Hull, United Kingdom Chelsea and Westminster Hospital, London, United Kingdom West Middlesex University Hospital, London, United Kingdom |